At a glance
ClinicalIndex Comparison RecordPhase 2Active· 62 enrolled
Drug / intervention
Anakinradrug
Likely dose
Anakinra 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells
In Brief
A Phase 2 clinical trial evaluating Anakinra for B Cell ALL and 2 related conditions. Active but no longer recruiting, targeting 62 participants across 2 sites.
Detailed Summary
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsB Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
TodayJul 2026
Primary CompletionOct 2026
First PostedNov 1, 2019
Enrollment StartOct 30, 2019
Primary CompletionOct 1, 2026
TodayJul 1, 2026
Enrollment to primary: 6.9 yearsPosted 6.7 years agoPrimary completion in 3 months
Interventions
Anakinradrug
100mg subcutaneous